The Journal of clinical endocrinology and metabolism
The most recent articles from:
June 2018
-
J. Clin. Endocrinol. Metab. · Jun 2018
Randomized Controlled Trial Multicenter StudySemaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin. ⋯ Semaglutide, added to basal insulin, significantly reduced HbA1c and body weight in patients with uncontrolled T2D vs placebo.